探索传统与靶向改善病情抗风湿药对银屑病关节炎患者体重的影响
基于1754例银屑病关节炎患者队列,评估不同DMARDs启动后一年体重变化。TNFi与一年体重增加相关(1.54 kg,P<0.01),其他药物类别未见显著变化;变更点模型显示IL-17i、IL-23i和csDMARDs启动后体重变化速率显著下降。TNFi和IL12/23i使用与体重增加相关,阿普米司特与体重减轻相关。
要点
- TNFi启动后一年体重较启动时增加1.54 kg(P<0.01),其他药物类别未见显著变化。
- IL-17i、IL-23i和csDMARDs启动后体重变化速率较启动前显著下降(P<0.01)。
- 随访中体重增加相关因素包括TNFi、IL12/23i、男性、随访时长和较高基线体重;体重减轻相关因素为阿普米司特、较大年龄和糖尿病。
核心结论
- 在银屑病关节炎患者中,启动IL-17i、IL-23i和csDMARDs后体重增加速率显著下降。
- 总体而言,TNFi和IL12/23i使用与体重增加相关,而阿普米司特与体重减轻相关。
研究设计与样本
- 分析大型银屑病关节炎患者队列数据,纳入至少两次随访体重测量的患者。
- 评估药物启动后一年绝对体重差异,比较未用药或NSAIDs、csDMARDs、TNFi、IL-12/23i、IL-17i、IL-23i、JAKis和阿普米司特各类别。
- 采用两个独立线性混合模型及变更点建模检查治疗启动前后体重变化趋势及随访中影响体重的因素。
主要发现
- 共1754例患者,其中473例使用NSAIDs或未用药,571例使用csDMARDs,702例使用bDMARDs,42例使用JAKi,70例使用阿普米司特。
- 与药物启动时体重相比,TNFi与一年体重增加相关(1.54 kg,P<0.01),其他药物类别未见显著变化。
- 变更点建模显示,与治疗启动前相比,IL-17i启动后体重变化速率显著下降(斜率0.63±0.20 vs -0.26±0.25,P<0.01)。
- IL-23i启动后体重变化速率显著下降(斜率0.82±0.34 vs -0.56±0.56,P<0.01),csDMARDs启动后亦显著下降(斜率0.43±0.24 vs -0.20±0.26,P<0.01)。
- 随访中体重增加相关因素包括TNFi、IL12/23i使用、男性、随访时长和较高基线体重;体重减轻相关因素包括阿普米司特、较大年龄和糖尿病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate change in body weight with DMARDs in PsA. METHODS: We analysed data from a large cohort of PsA patients with at least two weight measurements over follow-up. The absolute weight difference at one year from drug initiation was evaluated across-no medications or NSAIDs, conventional synthetic (cs) DMARDs, tumour necrosis factor inhibitors (TNFi), IL-12/23 inhibitor (i), IL-17i, IL-23i, Janus kinase inhibitors (JAKis) and apremilast classes. Two separate linear mixed models examined trends in weight change before and after treatment initiation with change-point modelling and factors affecting weight over follow-up. RESULTS: Of 1754 patients, 473 were on NSAIDs or no medications, 571 on csDMARDs, 702 on bDMARDs, 42 on JAKi and 70 on apremilast. Compared with weight at drug initiation, TNFi was associated with a weight gain at one year (1.54 kg, P < 0.01), whereas no significant change was observed with other drug classes. On change-point modelling, a significant decrease in the rate of weight change was observed following IL-17i (slope 0.63 ± 0.20 vs -0.26 ± 0.25, P < 0.01), IL-23i (0.82 ± 0.34 vs -0.56 ± 0.56, P < 0.01) and csDMARDs (0.43 ± 0.24 vs -0.20 ± 0.26, P < 0.01) compared with before treatment initiation. Factors associated with weight gain over follow-up included TNFi, IL12/23i use, male sex, follow-up duration and higher baseline weight, while with weight loss were apremilast, older age and diabetes mellitus. CONCLUSION: The rate of weight gain significantly decreases following the initiation of IL-17i, IL-23i and csDMARDs in PsA. Overall, TNFi and IL12/23i use is associated with weight gain, while apremilast with weight loss.
引用
- Mehta P, Kharouf F, Abarza VC, et al. Exploring the impact of conventional and targeted DMARDs on body weight in patients with PsA. Rheumatology (Oxford). 2025. PMID: 40408240. doi:10.1093/rheumatology/keaf277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。